Ann: Imugene completes $90 M placement and launches $5 M SPP, page-270

I'm hoping they do four agreements, one with each of the following companies:

They all have a vested interested in seeing onCARlytics succeed. They also have a vested interest in seeing onCARlytics remain only targeting CD19. What's it worth to each of them to have access to a $480 billion dollar market and retain exclusivity to that market for as long as possible. I hope the deal done by Imugene includes an upfront payment, funding for the clinical trials and a share of the sales from each of their drugs when used to treat solid tumours primed by onCARlytics.

Also consider onCARlytics could be on the market within a couple of years because all Imugene likley need to demonstrate is that solid tumour cells do become armed with the CD19 tag and that the CD19 CAR-Ts work against solid tumours armed with the CD19 tag.

(IMU's 10% share of $480b divided by IMU SOI payed out as a dividend multiplied by my share holdings... yeah, I'd be happy with that.)